LifeStance Health Group (NASDAQ:LFST) Major Shareholder Tpg Gp A, Llc Sells 13,643,207 Shares

LifeStance Health Group, Inc. (NASDAQ:LFST) major shareholder Tpg Gp A, Llc sold 13,643,207 shares of the business’s stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $10.62, for a total transaction of $144,890,858.34. Following the sale, the insider directly owned 98,101,407 shares of the company’s stock, valued at $1,041,836,942.34. This represents a 12.21% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Major shareholders that own at least 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

LifeStance Health Group Price Performance

LifeStance Health Group stock traded up $0.73 during midday trading on Wednesday, reaching $12.23. The company had a trading volume of 6,069,393 shares, compared to its average volume of 3,436,752. The company has a market capitalization of $4.74 billion, a P/E ratio of 94.08 and a beta of 1.14. LifeStance Health Group, Inc. has a 12-month low of $4.77 and a 12-month high of $12.43. The firm’s fifty day simple moving average is $10.10 and its 200-day simple moving average is $8.12. The company has a debt-to-equity ratio of 0.18, a current ratio of 1.38 and a quick ratio of 1.38.

LifeStance Health Group (NASDAQ:LFST) last posted its quarterly earnings data on Thursday, August 6th. The company reported $0.06 EPS for the quarter, topping the consensus estimate of $0.03 by $0.03. LifeStance Health Group had a return on equity of 3.39% and a net margin of 3.19%.The company had revenue of $435.35 million during the quarter, compared to analyst estimates of $414.58 million. During the same period in the previous year, the business earned ($0.01) EPS. LifeStance Health Group’s quarterly revenue was up 26.1% on a year-over-year basis. As a group, equities analysts anticipate that LifeStance Health Group, Inc. will post 0.14 EPS for the current year.

Institutional Trading of LifeStance Health Group

Large investors have recently added to or reduced their stakes in the stock. BlackRock Inc. purchased a new position in shares of LifeStance Health Group during the 2nd quarter worth $389,293,000. Vanguard Group Inc. boosted its position in shares of LifeStance Health Group by 21.1% during the 4th quarter. Vanguard Group Inc. now owns 17,700,041 shares of the company’s stock valued at $124,608,000 after acquiring an additional 3,086,506 shares during the last quarter. Silversmith Partners I GP LLC purchased a new stake in shares of LifeStance Health Group in the fourth quarter valued at about $100,842,000. Dimensional Fund Advisors LP grew its holdings in shares of LifeStance Health Group by 16.4% in the first quarter. Dimensional Fund Advisors LP now owns 10,367,680 shares of the company’s stock valued at $66,038,000 after purchasing an additional 1,461,215 shares during the period. Finally, Jennison Associates LLC increased its position in LifeStance Health Group by 38.5% during the first quarter. Jennison Associates LLC now owns 10,228,801 shares of the company’s stock worth $65,157,000 after purchasing an additional 2,843,388 shares during the last quarter. 85.50% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several brokerages have issued reports on LFST. Zacks Research cut shares of LifeStance Health Group from a “strong-buy” rating to a “hold” rating in a research note on Monday, July 13th. Canaccord Genuity Group increased their target price on shares of LifeStance Health Group from $11.00 to $13.00 and gave the company a “buy” rating in a research report on Tuesday, July 21st. BTIG Research raised their price target on shares of LifeStance Health Group from $15.00 to $16.00 and gave the stock a “buy” rating in a research note on Friday, August 7th. Wall Street Zen lowered shares of LifeStance Health Group from a “strong-buy” rating to a “buy” rating in a research report on Saturday, July 25th. Finally, Barclays upped their price objective on shares of LifeStance Health Group from $9.00 to $13.00 and gave the company an “overweight” rating in a research note on Tuesday, July 14th. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and four have assigned a Hold rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $11.62.

Key Headlines Impacting LifeStance Health Group

Here are the key news stories impacting LifeStance Health Group this week:

• Positive Sentiment: Analyst upgrades support the rally: BTIG Research raised its price target from $15 to $16 while maintaining a Buy rating. Morgan Stanley also reaffirmed its Buy rating, reinforcing Wall Street confidence in LifeStance’s growth prospects. BTIG Raises LifeStance Price Target Morgan Stanley Reaffirms Buy Rating
• Positive Sentiment: Zacks upgraded LFST to Rank #2 (Buy): The upgrade reflects growing optimism about LifeStance’s earnings prospects and could attract additional near-term buying interest. LifeStance Health Upgraded to Buy
• Positive Sentiment: Shares reached a new 52-week high after the analyst upgrade. The move reflects strong recent momentum, supported by LifeStance’s latest quarterly performance, which included revenue growth of 26.1% year over year and earnings above analyst expectations. LifeStance Sets New 52-Week High
• Neutral Sentiment: LifeStance released survey results highlighting demand for integrated mental-health services during perimenopause and menopause. The findings support the company’s brand and potential service demand but do not represent a direct financial forecast or new contract. LifeStance Menopause Mental Health Survey
• Negative Sentiment: COO Lisa K. Miller sold 47,912 shares worth approximately $520,000, reducing her ownership by 14.55%. While insider sales can be motivated by personal financial planning, the transaction may create a modest sentiment headwind after the stock’s strong advance. SEC Insider Trading Filing

LifeStance Health Group Company Profile

LifeStance Health Group (NASDAQ:LFST) is a leading provider of outpatient mental health services in the United States. Headquartered in New York City, the company operates a growing network of clinics that deliver integrated, patient-centered psychological and psychiatric care. LifeStance’s mission is to expand access to high-quality mental health treatment by combining evidence-based therapy modalities with personalized treatment plans.

The company’s service offerings include individual, family, and group psychotherapy, psychiatric medication management, psychological assessment, and telehealth services.